TaiMed Biologics (4147) — Cash Flow Reinvestment Rate

Latest as of December 2025: 2.64x

TaiMed Biologics (4147) has a Cash Flow Reinvestment Rate of 2.64x as of December 2025, reinvesting NT$68.58 Million (capex NT$16.75 Million plus investments NT$51.83 Million) from operating cash flow of NT$25.95 Million. Check 4147 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

2.64x

(Capex + Investments) / Operating CF

Total Reinvested

NT$68.58 Million

Capex + Investments

Operating Cash Flow

NT$25.95 Million

TWD

Capital Expenditures

NT$16.75 Million

TWD

TaiMed Biologics Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for TaiMed Biologics across 1 annual periods. Explore TaiMed Biologics (4147) investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for TaiMed Biologics (2025–2025)

Year-by-year capital reinvestment analysis for TaiMed Biologics. For live market cap and broader valuation context, see TaiMed Biologics market cap and net worth.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2025	1.04x	NT$199.46 Million	NT$191.14 Million	NT$22.77 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow